Depressive symptoms · adults with Major Depressive Disorder
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Acceptability ‐ total dropouts · adults with Major Depressive Disorder
It is very uncertain whether ketamine changes acceptability: total dropouts№ of participants: 201(6 RCTs) compared with placebo (very low certainty).
1 finding from 1 review
OR 1.25 [0.19, 8.28]
Studies not reported
Very low
Withdrawals due to adverse events · adults with Major Depressive Disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of oxygen therapy (hours) · patients with the management of transient tachypnea of the newborn
1 finding from 1 review
Need for continuous positive airway pressure (yes/no) · patients with the management of transient tachypnea of the newborn
It is very uncertain whether salbutamol changes need for continuous positive airway pressure (yes/no) compared with placebo/no treatment (very low certainty).
1 finding from 1 review
Need for mechanical ventilation · patients with the management of transient tachypnea of the newborn
It is very uncertain whether salbutamol changes need for mechanical ventilation (yes/no) compared with placebo/no treatment (very low certainty).
1 finding from 1 review
Duration of respiratory support (intermittent positive pressure ventilation or continuous positive airway pressure; hours). · patients with the management of transient tachypnea of the newborn
1 finding from 1 review
Length of hospital stay · patients with the management of transient tachypnea of the newborn
1 finding from 1 review
Duration of mechanical ventilation · patients with the management of transient tachypnea of the newborn
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pneumothorax · patients with the management of transient tachypnea of the newborn
It is very uncertain whether salbutamol changes pneumothorax (yes/no) compared with placebo/no treatment (very low certainty).
1 finding from 1 review
All‐cause mortality · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes all‐cause mortality compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Cardiovascular events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes cardiovascular events compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Total serious adverse events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes total serious adverse events compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Heart failure hospitalisation (RR) · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes hospitalisation for heart failure compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes withdrawal due to adverse events compared with placebo or no treatment (very low certainty).
1 finding from 1 review
50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy
Carisbamate probably leads to higher 50% or greater reduction in seizure frequency (responder rate) compared with placebo (moderate certainty).
1 finding from 1 review
Seizure freedom · people with drug‐resistant focal epilepsy
It is very uncertain whether carisbamate changes seizure freedom compared with placebo (very low certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
It is very uncertain whether carisbamate changes treatment withdrawal for any reason compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with drug‐resistant focal epilepsy
It is very uncertain whether carisbamate changes treatment withdrawal due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Participants who experienced any adverse event Adverse event regardless of severity · people with drug‐resistant focal epilepsy
Carisbamate showed no clear difference in proportion of participants who experienced atleast 1 adverse event compared with placebo (low certainty).
1 finding from 1 review